MedTrace Logo

Topical Allstate and Nasal Allergen Challenge

NCT01231724 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-06-03

No results posted yet for this study

Summary

The purpose of this study is to see whether Allstate Nasal Spray when given in the nose is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).

Conditions

  • Allergic Rhinitis

Interventions

DEVICE

Allstate Nasal Spray

Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.

DEVICE

Placebo Nasal Spray

2 sprays in each nostril

Sponsors & Collaborators

  • McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Robert M Naclerio, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-02-29
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231724 on ClinicalTrials.gov